They develop a new effective vaccine even for the next coronavirus pandemic

Four years after a coronavirus cause a global emergency, scientists have already developed a new technology of vaccines which, they have shown in mice, protects against a wide range of coronaviruses with potential for future outbreaks of the disease, including some that we don’t even know about yet.

This is a new approach, called “proactive vaccinology”in which scientists create a vaccine even before the pathogen that causes the disease appears.

The new vaccine trains the body’s immune system to recognize specific regions of eight different coronaviruses, including SARS-CoV-1, SARS-CoV-2 and several that are currently circulating among bats and that could jump to humans and cause a pandemic.

The key to its effectiveness is that the specific regions of the virus targeted by the vaccine also appear in many related coronaviruses.

By training the immune system to attack these regions, it protects against other coronaviruses not represented in the vaccine, including some that have not yet been identified.

For example, the vaccine does not include the SARS-CoV-1 coronavirus, which caused the SARS outbreak in 2003, but still induces an immune response against it.

Details of the research, carried out by scientists from the University of Cambridge, the University of Oxford and Caltech, were published this Monday in the journal Nature Nanotechnology.

A vaccine against viruses that we do not yet know

“We have created a vaccine that provides protection against a wide range of different coronaviruses, including some we don’t know about yet,” says Rory Hills, researcher at the University of Cambridge and first author of the study.

“We don’t have to wait for new coronaviruses to emerge. “We know enough about coronaviruses and their different immune responses to start building protective vaccines against unknown coronaviruses,” adds Mark Howarth, from the University of Cambridge and co-senior author.

The new vaccine “Quartet Nanocage” It is based on a structure called a nanoparticle, a ball of proteins held together by incredibly strong interactions.

Through a novel ‘protein superglue‘, chains of different viral antigens attach to this nanoparticle, training the immune system to target specific regions shared by a wide range of coronaviruses.

This study demonstrated that the new vaccine elicits a broad immune response, even in mice pre-immunized with SARS-CoV-2.

Clinical trials by 2025

The design of the new vaccine is much simpler than other broadly protective vaccines currently in development, which researchers say should accelerate its move to clinical trials.

The underlying technology they have developed also has the potential to be used in the development of vaccines that protect against many other health problems.

This is an improvement on previous work, carried out by the Oxford and Caltech groups, to develop a novel vaccineb against the threats of coronaviruses.

The vaccine developed by Oxford and Caltech should enter phase 1 clinical trials in early 2025, but its complex nature makes it difficult to manufacture, which could limit its large-scale production.

It may interest you

• COVID-19: house-to-house vaccination begins with monovalent and bivalent doses in Lima
• What is known about Pirola, the contagious variant of COVID-19
• COVID is back. Who is most likely to get it again?